logo
Share SHARE
FONT-SIZE Plus   Neg

Willis Group Appoints Gioia Ghezzi As COO

Insurance broker Willis Group Holdings plc (WSH) said Monday that it has appointed Gioia Ghezzi as Chief Operating Officer, effective immediately.

In her new role, Ghezzi will oversee a number of corporate functions and manage a global structure designed to drive revenue growth and increase operational efficiencies across the Group. She succeeds Tim Wright, now the CEO of Willis International, who served in the Chief Operating Officer role for four years.

Ghezzi joins Willis Group most recently from McKinsey & Co, where she spent 11 years as partner and leader of the Insurance and Health practices providing advice on company strategy, operations, and performance transformation to a large number of global clients.

Willis Group also said that Adam Rosman will be appointed Group General Counsel, overseeing the Group's worldwide legal, compliance, risk, corporate secretary, and audit functions.

Rosman has served as Group Deputy General Counsel and General Counsel for Willis North America for the past three years. He succeeds Adam Ciongoli, who is leaving the company in May to serve as General Counsel of Lincoln Financial Group.

Ghezzi will be based at the Willis building in London while Rosman will remain in New York.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Coca-Cola Company (KO) reported a profit for the first-quarter of 2017 that declined 20 percent from the prior year. Net revenues declined 11%, reflecting unfavorable impacts from structural changes of 10% and foreign currency of 1%. The company remains on track to deliver its underlying revenue and profit targets for the full year. Eli Lilly and Co. (LLY) reported a loss for the first quarter of 2017 compared to profit in the prior year, primarily hurt by lower operating income, partially offset by higher other income. But, quarterly revenue increased 7 percent, driven by 9 percent pharmaceutical volume growth from Trulicity, Taltz and other new products. Capricor Therapeutics, Inc., a clinical-stage biotechnology company for cardiac and other medical conditions, announced Tuesday positive six-month results from the randomized phase I/II HOPE clinical trial in Duchenne muscular dystrophy or DMD. The HOPE clinical trial was designed to evaluate the safety and exploratory efficacy of CAP-1002.
comments powered by Disqus
Follow RTT